You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cardiovascular conditions
  5. Embolism and thrombosis

Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation

  • Technology appraisal guidance
  • Reference number: TA275
  • Published:  27 February 2013
  • Last updated:  02 July 2021
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: expert written personal statements

  • Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: Diane Eaton - appendix K patient/carer declaration statement

  • Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: Jo Jerrome - appendix K patient/carer declaration statement

  • Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: Professor Gregory Lip - appendix D clinical specialist statement

  • Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: Dr Francis Murgatroyd - appendix K clinical specialist statement

  • Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: Dr Watts - appendix K clinical specialist statement


This page was last updated: 21 January 2013

Back to top